We’ve written about Withings multiple times on Health Tech Insider. We covered Withings’ wearables including smartwatches, smart scales, blood pressure monitors, ECG watches, temperature monitors, sleep aids, and more. We tracked Nokia’s acquisition of Withings and the subsequent parting of ways when Withings’ founder bought the company back. Withings rocked CES 2020 earlier this month when it announced the ScanWatch, Withings’ clinically tested hybrid health tech wearable smartwatch.
The ScanWatch has a combined heart rate and SpO2 sensor, three electrodes, and an altimeter. The watch’s rechargeable battery can last up to 30 days per charge, according to Withings, removing one of the greatest barriers to consistent use: the need for frequent charging.
The ScanWatch uses an algorithm to analyze the wearer’s heart rate 24/7 and reports when the rate is too high or too low, or when the watch detects irregular rhythms. Withings claims the ScanWatch can detect atrial fibrillation in just 30 seconds for early notice for both the wearer and their care team. Embedded SpO2 sensors in the ScanWatch monitor oxygen saturation in your blood and wake the wearer in the event of a sleep apnea episode.
On the fitness side of the ScanWatch’s feature ledger, the device helps improve cardiovascular fitness with VO2 max scores, an altimeter to track floors climbed, and 50-meter-depth water resistance so you can wear it swimming.
The ScanWatch has a digital crown with a bright PMOLED screen, and sapphire glass for strength, durability, and scratch-resistance. The watch can also display smartphone notification and alerts as well as create a viewable workout map when connected with a smartphone GPS.
Pending FDA and CE certifications, the Withings ScanWatch is an upcoming wearable that bears watching. Billed as a “Proactive Health Tracking” device, the ScanWatch is scheduled to launch in the second quarter of 2020 priced from $250 to $300 depending on watch face size.
